<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Quandary</title>
	<atom:link href="http://www.tapanray.in/tag/quandary/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>In a Quandary of Drug Quality, Price Control, Innovation and Patient Interest in India</title>
		<link>http://www.tapanray.in/in-a-quandary-of-drug-quality-price-control-innovation-and-patient-interest-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=in-a-quandary-of-drug-quality-price-control-innovation-and-patient-interest-in-india</link>
		<comments>http://www.tapanray.in/in-a-quandary-of-drug-quality-price-control-innovation-and-patient-interest-in-india/#comments</comments>
		<pubDate>Mon, 06 Mar 2017 00:00:21 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[denial]]></category>
		<category><![CDATA[Director]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[effective]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[mode]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[pharmacovigilance]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Quandary]]></category>
		<category><![CDATA[Que Sera]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[safe]]></category>
		<category><![CDATA[Sera]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[US-FDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8120</guid>
		<description><![CDATA[The patients in India have every reason to apprehend, whether the prescription drugs that they consume are efficacious, safe and conform to the government approved prices, alongside another important question: Do they affordable access to the fruits of innovation? The &#8230; <a href="http://www.tapanray.in/in-a-quandary-of-drug-quality-price-control-innovation-and-patient-interest-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/in-a-quandary-of-drug-quality-price-control-innovation-and-patient-interest-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
